Drugs / Cobenfy
Cobenfy cost
xanomeline and trospium chloride · Bristol Myers Squibb. Every official price for Cobenfy, side by side, with who pays it.
Short answer
FDA approved Cobenfy (xanomeline and trospium chloride) on Sep 26, 2024. Bristol Myers Squibb lists Cobenfy at $1,887 per 30-day supply, as of October 2026 (when we checked; the page gives no date). Pharmacies paid an average of $30.12–$30.25 per capsule (NADAC, Oct 21, 2026). In 2024, Medicare Part D spent $2.7 million on Cobenfy, an average of $1,556.59 per prescription fill before rebates (CMS). In Medicare Part D, the yearly out-of-pocket limit is $2,100 in 2026 and $2,400 in 2027.512634
Source: FDA, Bristol Myers Squibb, CMS, data.medicaid.gov (NADAC) and Medicare.gov · checked Nov 15, 2026
Cobenfy: the official numbers, by situation
| Price | Amount | Whose price, and who it applies to | Date |
|---|---|---|---|
| List price per 30-day supply | $1,8871 | Bristol Myers Squibb's price to wholesalers (WAC). Most people don't pay it directly. | October 2026 (when we checked; the page gives no date) |
| Pharmacy cost (NADAC) per capsule; a month depends on your dose | $30.12–$30.252 | What pharmacies pay on average (CMS survey). Not a patient price. | Oct 21, 2026 |
On Medicare drug coverage: 5,492 of 5,492 Part D plans list Cobenfy for 2027 (100%), and 53% of those require prior authorization, in CMS's formulary file published Oct 15, 2026.12 By year and tier
None of these is your price at the counter: that depends on how you pay. Details and sources for each number are further down.
FDA approval
- Approved by the FDA on Sep 26, 2024 as a new drug (xanomeline and trospium chloride).5
- FDA-approved use on the approval date, in FDA's words: "To treat schizophrenia."5 The current label may list more uses; ask your doctor or pharmacist what applies to you.
Every official price
| Price | Amount | What it is | Date |
|---|---|---|---|
| Maker's list price (WAC) | $1,8871 | Per 30-day supply. The price the maker charges wholesalers; most people do not pay it directly. | October 2026 (when we checked; the page gives no date) (checked Oct 25, 2026) |
| Pharmacy acquisition cost (NADAC) Cobenfy 100 mg-20 mg Capsule | $30.132 | Per capsule. The national average price pharmacies pay to buy it. | Oct 21, 2026 |
| Pharmacy acquisition cost (NADAC) Cobenfy 125 mg-30 mg Capsule | $30.252 | Per capsule. The national average price pharmacies pay to buy it. | Oct 21, 2026 |
| Pharmacy acquisition cost (NADAC) Cobenfy 50 mg-20 mg Capsule | $30.232 | Per capsule. The national average price pharmacies pay to buy it. | Oct 21, 2026 |
| Pharmacy acquisition cost (NADAC) Cobenfy Starter pack | $30.122 | Per tablet or capsule in the pack. The national average price pharmacies pay to buy it. | Oct 21, 2026 |
These are prices the drug company, Medicare and pharmacies use. What you pay depends on your coverage; see below.
What Medicare spent on Cobenfy in 2024
CMS publishes what Part D spent on each drug each year. Its spending is the gross drug cost, which includes what Medicare, the plan and the patient paid,7 and it does not reflect manufacturers' rebates.8 CMS lists Cobenfy in 2 rows; together they come to $2.7 million over 1,749 prescription fills, $1,556.59 per fill.
Medicare Part D, calendar year 2024 (CMS Medicare Part D Spending by Drug, checked Nov 15, 2026).
| Product (as CMS lists it) | Total spending | Fills | People | Per fill | Per person |
|---|---|---|---|---|---|
| Cobenfy | $2.4 million6 | 1,539 | 961 | $1,533.179 | $2,455.3110 |
| Cobenfy Starter Pack | $0.4 million6 | 210 | 204 | $1,728.189 | $1,779.0110 |
These are totals and averages across everyone in Medicare who used the drug, not a price for one person. Averages per person depend on how long and how much each person used it.
How many Medicare Part D plans list Cobenfy
Every Medicare drug plan in CMS's formulary file (standalone drug plans and Medicare Advantage plans with drug coverage). A plan counts when its drug list has at least one form or strength. Matched by RxNorm code and checked against the FDA NDC Directory. Plan counts, not people; to see your own plan's rules use Medicare Plan Finder.
| Plan year | Plans that list it | Prior auth. | Step therapy | Quantity limit | Lowest tier (plans) |
|---|---|---|---|---|---|
| 2026 | 5,496 of 5,49611 100% | 3,042 | 466 | 5,234 | tier 1: 161 · tier 2: 2 · tier 3: 55 · tier 4: 1,376 · tier 5: 3,882 · tier 6: 20 |
| 2027 | 5,492 of 5,49212 100% | 2,921 | 422 | 5,315 | tier 1: 123 · tier 2: 1 · tier 4: 1,006 · tier 5: 4,362 |
Being on a plan's list is not a price: what you pay depends on the tier and your plan. Each plan can divide its tiers in different ways. What prior authorization, step therapy and tiers mean.
With Medicare
- What you pay depends on your Part D plan. The rules that apply to every Part D drug, from the deductible to the $2,400 out-of-pocket limit in 2027, Extra Help and the Medicare Prescription Payment Plan, are on one page: Part D costs · payment plan. Free one-on-one help: a SHIP counselor or 1-800-MEDICARE.
With commercial insurance or no insurance
- What you pay depends on your plan's copay or coinsurance. The maker lists its savings and support options here: Bristol Myers Squibb: COBENFY support program. We link to it but do not copy its terms.
Which drug, which dose, and whether to start, stop or switch are medical decisions. Ask your doctor or pharmacist.
Get an email when a price or rule changes
Only when an official GLP-1 self-pay price or a Medicare or Medicaid rule changes, at most once a week, with the official source for every change.
Official sources for this page (12)
“The Wholesale Acquisition Cost (WAC), also known as list price, is $1,887 for 30 days of COBENFY. However, the WAC may not reflect the price paid by customers.”
Bristol Myers Squibb: Cobenfy pricing (entered by hand) · as of Oct 25, 2026- data.medicaid.gov: NADAC (National Average Drug Acquisition Cost) 2026 · as of Oct 25, 2026
“Out-of-pocket limit Yearly $2,100 (in 2026).”
Medicare.gov: Medicare costs · as of Oct 23, 2026“Out-of-Pocket Threshold: $2,100 Out-of-Pocket Threshold: $2,400”
CMS: CY 2027 Medicare Advantage and Part D Rate Announcement (Table V-6) · as of Oct 23, 2026“Cobenfy xanomeline and trospium chloride 9/26/2024 To treat schizophrenia”
FDA: Novel Drug Approvals for 2024 · as of Oct 25, 2026“Cobenfy: Tot_Spndng_2024 2359549.66, Tot_Clms_2024 1539, Tot_Benes_2024 961; Cobenfy Starter Pack: Tot_Spndng_2024 362917.98, Tot_Clms_2024 210, Tot_Benes_2024 204”
CMS: Medicare Part D Spending by Drug, 2024 (data.cms.gov) · as of Nov 15, 2026“Drug spending metrics for Part D drugs are based on the gross drug cost, which represents total spending for the prescription claim, including Medicare, plan, and beneficiary payments.”
CMS: Medicare Part D Spending by Drug (about the data) · as of Nov 15, 2026“The Part D spending metrics do not reflect any manufacturers' rebates or other price concessions as CMS is prohibited from publicly disclosing such information.”
CMS: Medicare Part D Spending by Drug (about the data) · as of Nov 15, 2026“Part D drug spending divided by the number of prescription fills.”
CMS: Medicare Part D Spending by Drug data dictionary · as of Nov 15, 2026“Total Part D drug spending divided by the number of unique beneficiaries utilizing the drug during the benefit year.”
CMS: Medicare Part D Spending by Drug data dictionary · as of Nov 15, 2026- CMS: 2026_20260916.zip (Part D formulary file for 2026 plans, published 2026-09-23) · as of Nov 15, 2026
- CMS: 2027_20261008.zip (Part D formulary file for 2027 plans, published 2026-10-15) · as of Nov 15, 2026